盘点2015年生物医学大事件

2015-12-03 孙学军 科学网

每年年底,一定会有许多总结。科学研究也一样,过去《自然》和《科学》已经许多研究机构都会有这类总结。能准确把握学术热点,本身就是科学鉴赏力的表现。我自认为鉴赏力有限,但毕竟是这个圈子内的,这里先尝试一下,作为抛砖引玉。希望大家能批评补充。一、中国女科学家屠呦呦获得诺贝尔生理学或医学奖。这是中国科学家首次在中国本土研究获得的诺贝尔科学类奖,具有重要的里程碑意义。从次以后,中国彻底摘掉诺贝尔科学家零的帽

每年年底,一定会有许多总结。科学研究也一样,过去《自然》和《科学》已经许多研究机构都会有这类总结。能准确把握学术热点,本身就是科学鉴赏力的表现。我自认为鉴赏力有限,但毕竟是这个圈子内的,这里先尝试一下,作为抛砖引玉。希望大家能批评补充。

一、中国女科学家屠呦呦获得诺贝尔生理学或医学奖。

这是中国科学家首次在中国本土研究获得的诺贝尔科学类奖,具有重要的里程碑意义。从次以后,中国彻底摘掉诺贝尔科学家零的帽子。当然作为一个有重要影响力的大国,这种国际级的科学奖应该成为常规和日常新闻,但那一天不知道什么时候才会到来,但是我们有信心。因为历史反复证明,中国人都是炎黄子孙,聪明就从来不是个事。只是科学发展的历史比较短,没有发掘出我们的潜力。

二、中国学者发现磁感受分子。

这个所以成为第二,不仅是因为这个重要发现比较引人注目,更在是背后有一些故事,到现在仍然没有弄清楚。

三、美国FDA批准转基因三文鱼上市。

关于转基因的话题,不仅是科学问题,也是社会热门话题。在大家纠结于转基因危害的时候,国际上对食品药品安全性要求最高级别的美国FDA,竟然给一家公司批准转基因鱼可以销售。为什么可以销售,主要的依据是没有证据说明这种鱼对人会产生危害,没有证据说明这种鱼能引起环境危害。虽然如此,考虑到许多人的各种角度的担心,仍然限制这种鱼只能这个公司饲养,避免流失到野外造成无法确定的环境危害。

四、维生素C抗癌

维生素C简直就是一个传说,发现这个维生素有许多故事。对这个物质的崇拜也成为上世纪受争议的话题,上世纪这个传说的最重要推动者就是双诺贝尔奖获得者鲍林。当时一直没有获得比较确定的证据,特别是后来进行的临床研究否定了这一说法。不过一直有学者坚持维生素C抗癌症的看法,这次似乎是一场漂亮的翻身战。因为这个研究论文发表在《科学》杂志上。而且从分子机制角度对这一表型进行了比较符合逻辑的分析。但是使用剂量非常大才有效果的问题仍然是这一研究存在的尴尬。

五、人类基因组编辑

生物技术突飞猛进,一个重点体现就是能简单地对物种基因组进行编辑。这一工作过去是依靠自然突变和长期的自然环境选择缓慢进行的,从低等生物到高等生物就是这样进化过来的。如今人类掌握了这一技术,意味着能加快基因甚至物种的进化。尤其是对人类自身的基因组,是编辑还是不编辑,十分让人纠结。2015年12月1-3日,华盛顿召开一次大型国际会议会议专门讨论人类基因组编辑的伦理学问题。

六、癌症免疫治疗方法突飞猛进

安进溶癌病毒在美上市,其他多种免疫治疗药物先后上市并取得了非常不错的效果。这一领域也迅速成为医药公司重点投入和竞争的热点。

七、火腿、香肠、肉干被列为致癌物

被列为致癌物的东西有许多,也是世界卫生组织的国际癌症研究所的份内工作。但是这次被列入的成员比较特殊,因为这是许多人的日常饮食。

八、Springer公司大批撤回中国学者伪评审论文

几乎都是来自生物医学领域,几乎全部都是中国学者。这个事已经被大家和国际多个大媒体广泛讨论,丢人丢到全世界。不是热点也是热点的黑色话题。

九、埃博拉疫苗成功

埃博拉是一个让人恐惧的疾病,人类使用疫苗能有效预防这一疾病给控制这一疾病带来了关键条件。这一点就可以说明其重要性。

十、美国总统奥巴马提出精准医学

美国总统奥巴马在2015年国情咨文演讲中谈到了“人类基因组计划”(Human Genome Project)所取得的成果,并宣布了新的生物医学项目——精准医疗计划(Precision Medicine Initiative)。这是奥巴马总统继大脑研究计划后,再次利用年度国情咨文演讲的机会,发布生物医学研究的纲领性倡议。

总起来看,2015年不是一个有重大成果的年度,也许在最后这一个月有能让人眼前一亮的东东。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
    2016-03-14 wei834766788

    呵呵

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
    2015-12-27 hixiaoluo

    自豪

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
    2015-12-03 老段

    意义重大

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
    2015-12-03 王新春

    好的

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
    2015-12-03 zhouanxiu

    好好

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=69465, encodeId=ef7d6946578, content=呵呵, beContent=null, objectType=article, channel=null, level=null, likeNumber=121, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Mon Mar 14 22:57:00 CST 2016, time=2016-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=49106, encodeId=cbf949106b5, content=自豪, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sun Dec 27 09:06:00 CST 2015, time=2015-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1461451, encodeId=d2e4146145194, content=<a href='/topic/show?id=06a069243aa' target=_blank style='color:#2F92EE;'>#生物医学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69243, encryptionId=06a069243aa, topicName=生物医学)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=医者仁心, createdTime=Sat Dec 05 01:08:00 CST 2015, time=2015-12-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44615, encodeId=555644615f4, content=意义重大, beContent=null, objectType=article, channel=null, level=null, likeNumber=167, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2d331664955, createdName=老段, createdTime=Thu Dec 03 21:32:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44558, encodeId=36354455854, content=好的, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3xSHQO6hUsLfmSqiaQiceT0D77ib0rXiblAIwyTo0iciakSAGHE0nfEpNHl9icHMY6tKTW3kFdWSwKcWGvneZHicqoJsI5V/0, createdBy=2a221626427, createdName=王新春, createdTime=Thu Dec 03 16:54:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44549, encodeId=d01244549aa, content=好好, beContent=null, objectType=article, channel=null, level=null, likeNumber=133, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3yz0JbjHQ7nicJU7lHMOu0Itf3Zv3VBzEvK3k4AFPBXhiaxIRNGVI33GicoRXQEjkaasjdlWKwZuwcyhDP9Jibqt5ct/0, createdBy=f1281613275, createdName=zhouanxiu, createdTime=Thu Dec 03 14:51:00 CST 2015, time=2015-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=44511, encodeId=6107445119d, content=行了,很好,很好, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJXCR8W80NNgQuicJU3aIm3JtiaNAFLYSMlBuVfGkSlw5Z5VpmZK4PyiaDURLAorhvwhWVnaM1gQdJXA/132, createdBy=a01444383, createdName=lixh1719, createdTime=Thu Dec 03 11:11:00 CST 2015, time=2015-12-03, status=1, ipAttribution=)]
    2015-12-03 lixh1719

    行了,很好,很好

    0

相关资讯

科技部:2014年973计划验收结果(生物医学领域)

近日,科技部按照《国家重点基础研究发展计划(973计划)管理办法》和《国家重点基础研究发展计划专项经费管理办法》有关规定,完成了973计划(含重大科学研究计划)2010年立项137个项目、2012年立项2个项目和2013年立项2个项目的结题验收。现将项目验收结果通知如下: 1.“主要农作物核心种质重要农艺性状单元型区段及互作研究”等141个项目自立项实施以来,总体执行情况较好,达到了预期目

2015生物医学八大就业岗位发布

在2009-2014年间,辉瑞(Pfizer)一共裁员38200名,默沙东(Merck & Co)一共裁员30000名。2015年尚未出现过去五年那样的大裁员,但趋势依旧存在,阿斯利康将在2016年减少5600个职位,而安进明年也会减少4000个,葛兰素史克则表示计划裁员900个。然而一线希望出现,大型药企引入的新疗法使得空缺职位开始增加。美国劳工统计局(BLS)对某些生物医药职位仍持乐观

Nature:进化路上,再生能力消失了……

一个来自柏林für Naturkunde博物馆的古生物学家团队以及布朗大学对两栖类动物化石的合作研究认为现代火蜥蜴的强大再生功能源于其四足脊椎动物祖先,而在漫长的进化中这一特异功能却逐渐地消失了。 火蜥蜴是四足脊椎动物中的佼佼者,它们天然拥有强大的再生能力。在一生中,它们的外肢、尾巴、以及内在器官等在损伤之后都能通过再生恢复。它们的这一特性内在的机制一直以来也是科学家们十分感兴趣的问题,希

美国每年有280亿美元生物医学研究不可重复

6月9号发表在《PLoS生物学》上的一篇论文称,美国科学家每年在不能重复的基础生物医学研究上花费280亿美元。 斯坦福大学流行病学家John Ioannidis称,该项研究推动了不可重复性研究问题的进一步讨论,但这个结论带有不确定性。论文第一作者,非营利性组织全球生物标准协会会长 Len Freedman认为,尽管不能确定不可重复性研究问题的严重程度,但这项研究是有价值的。 Len Freed

2015年度国家科学技术奖励受理项目(生物医学)

国家科学技术奖励工作办公室公告第77号 2015年度国家科技奖励推荐工作已经结束,我办共收到有关单位和科技专家推荐的国家自然科学奖项目138项,国家技术发明奖200项(通用项目157项,专用项目43项),国家科学技术进步奖576项(通用项目459项,专用项目117项)。经我办形式审查,3项国家自然科学奖项目、7项国家技术发明奖通用项目、1项国家技术发明奖专用项目、22项国家科学技术进步奖通用

追寻抗体生产的标准化

百余位科学家联名呼吁生物医学研究采用重组抗体 我们呼吁发起一个全球合作和资助项目,旨在对所有结合试剂根据编码序列作出界定。 图片来源:Pete Ellis/drawgood.com 生物医学研究中重现性的核心在于,能使用和已发表论文中所描述的完全相同的试剂。但令人担忧的是,应用最广泛的蛋白结合试剂——抗体的可靠性存在严重缺陷。 在生物体内,抗体能帮助对抗病原